Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Present Da

DUBLIN, March 15, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present five new abstracts at the American Association

Related Keywords

United States , China , Ireland , Dublin , American , Dennis Riedl , Pharma Mar , Zymework Azymetric , Kristin Bhavnani , Andrean Flynn , Rob Iannone , Jazz Pharmaceuticals Inc , Commission File No , Jazz Pharmaceuticals , Drug Administration , Beigene Ltd , Head Of Global Corporate Communications , Nasdaq , Exchange Commission , American Association For Cancer Research , Prnewswire Jazz Pharmaceuticals , European Medicines Agency , American Association , Cancer Research , Annual Meeting , Therapeutic Benefit , Cell Death , Molecular Classifications , Methyltransferase Inhibitors , Phasei Clinical Trials , Immunomodulatory Agents , Monday April , Breakthrough Therapy , Fast Track , Orphan Drug , Drug Evaluation , Safety Information , Full Prescribing Information , Patient Information , Werewolf Therapeutic , Jazz Pharmaceutical , Commission File , Jazz Pharmaceutical Annual Report , Media Contact , Global Corporate , Investor Contact , Palo Alto , Jazz , Pharmaceuticals , Present , Data , 023 , Racr , Nnual , Meeting , Howcasing , Epzelca , Lurbinectedin , Xpanded , Ncology , Linical , Pipeline ,